Not connected to live PC
January 2010 Table of Contents
 SUBSCRIBE TODAYRSS FeedRSS Feeds
Search
Search

Other issues: December 2009 | January 2010

Pointed View
Public Interest/Private Sector: Perspectives on Conflict of Interest

Conflict of interest remains a thorny topic in the conduct, analysis and dissemination of clinical trials. Four panelists on a recent Windhover Webinar offer their perspectives on how private companies can best align with the public interest goals of medical research. . . . [MORE . . .]

FDA Beat
Antibiotic Susceptibilty Re-labeling Increases FDA Susceptibility To New Political Challenges

The FDA faces a difficult, legislatively-mandated requirement in the anti-infective area. It is charged with updating antibioitic susceptibility charts in labeling for all approved anti-infectives. That is a huge task -- almost equivalent to re-reviewing the large cadre of existing antibiotic drugs. To try to achieve the task, the agency has proposed trusting an outside standards group for help. That sounds like a practical solution; but Capitol Hill has political problems. . . . [MORE . . .]

Street Smarts
The Year of the Unpartnered Blockbuster? High Profile Applications Raise Big Questions

Several of the highest profile new drug applications pending or expected to be submitted as 2010 begins involve potential blockbuster market opportunities. They also lack Big Pharma partners. Is Big Pharma really that picky? Or are the applications out of step with the regulatory and commercial climate? Either way, intense investor interest will keep FDA in the spotlight. . . . [MORE . . .]

Free Speech
Free Speech Jan. 2010

Government and industry leaders discuss follow-on biologics, reverse payments and health care refrom. . . . [MORE . . .]

Feature Articles
Health Reform in the Balance: What It Means for Biopharma

The long road to enacting health reform appeared to be close to an end with final negotiations taking place in the White House. But the Senate race for Ted Kennedy's open seat in Massachusetts has put the bill, and pharma's hard-fought concessions, in the breach. . . . [MORE . . .]

CMS Beat
The Triumph of Part D

The US prescription drug market remains anemic, but don't blame the federal government. The Medicare Prescription Drug Benefit that began in 2006 is the only reason there has been any growth in the retail sector. No wonder industry is so eager for health care reform. . . . [MORE . . .]

Feature Articles
No Fault? Not Quite

An HHS departmental appeals board decision finds Purdue executives at fault despite plea and convictions based solely on the Dotterweich and Park doctrines . . . [MORE . . .]

FDA Beat
Opening Up the Black Box: FDA Wants To Make "Complete Response" Letters Public

FDA's transparency initiative is starting to take shape. While many industry executives see the value in making more information available to the public, one idea makes them nervous: publicizing the letters FDA sends when it declines to approve a new drug or biologic. Top FDA officials already support making "complete response" letters public, and the Commissioner's office is open to the idea. How should industry prepare? . . . [MORE . . .]

Other Publications: "The Pink Sheet" DAILY | "The Pink Sheet" | "The Gray Sheet" | "The Rose Sheet" | "The Tan Sheet" | Pharmaceutical Approvals Monthly | PharmAsia News
IN VIVO | Start-Up | The RPM Report | Medtech Insight